Low bone mineral density in patients with well-suppressed HIV infection: Association with body weight, smoking, and prior advanced HIV disease

Journal of Infectious Diseases

Volumn 211, Issue 4, 2015, Pages 539-548

  Kooij, Katherine W ^a   Wit, Ferdinand W N M ^a,b   Bisschop, Peter H ^c   Schouten, Judith ^a,c   Stolte, Ineke G ^b,d   Prins, Maria ^b,d   Van Der Valk, Marc ^b   Prins, Jan M ^b   Van Eck Smi, Berthe L F ^a   Lips, Paul ^e   Reiss, Peter ^a,b,f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Center for Infection and Immunity Amsterdam CINIMA   (Netherlands)

^c Department of Endocrinology and Metabolism ^*  (Netherlands)

^d DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f STICHTING HIV MONITORING   (Netherlands)

Author keywords

body weight; bone mineral density; HIV; men who have sex with men; osteopenia; osteoporosis

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; OSTEOPENIA; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; SMOKING; COMPLICATION; HIV INFECTIONS; MALE HOMOSEXUALITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

BODY WEIGHT; BONE DENSITY; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PROSPECTIVE STUDIES; SMOKING;

EID: 84922454148     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu499     Document Type: Article

References (40)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of os-teopenia and osteoporosis: a meta-analytic review. AIDS Lond Engl 2006; 20:2165-74.
2. Young B, Dao CN, Buchacz K, Baker R, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-8.
3. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PloS One 2011; 6:e17217.
4. Prieto-Alhambra D, Güerri-Fernández R, De Vries F, et al. HIV infection and its association with an excess risk of clinical fractures: a nationwide case-control study. J Acquir Immune Defic Syndr 1999 2014; 66:90-5.
5. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 1999 2009; 51:554-61.
6. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-801.
7. Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72.
8. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS Lond Engl 2009; 23:817-24.
9. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-601.
10. Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PloS One 2012; 7:e32445.
11. Cotter AG, Vrouenraets SME, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients: a substudy of the PREPARE study. J Clin Endocrinol Metab 2013; 98:1659-66.
12. Tebas P, Zhang J, Yarasheski K, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 1999 2007; 45:193-200.
13. Ofotokun I, Sheth AN, Sanford SE, et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses 2012; 28:1196-206.
14. Bolland MJ, Wang TKM, Grey A, Gamble GD, Reid IR. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab 2011; 96:2721-31.
15. Moyle GJ, Stellbrink H-J, Compston J, et al. 96-Week results of abaca-vir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antire-troviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther 2013; 18:905-13.
16. Assoumou L, Katlama C, Viard J-P, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS Lond Engl 2013; 27: 2425-30.
17. Bolland MJ, Grey AB, Gamble GD, Reid IR. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007; 92:4522-8.
18. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012; 205(suppl 3):S391-8.
19. Amsterdam Cohort Studies on HIV/AIDS. http://www.amsterdam cohortstudies.org. Accessed 13 May 2014.
20. 2013 ISCD official positions-adult. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/. Accessed 13 May 2014.
21. Stichting HIV monitoring. http://www.hiv-monitoring.nl/english/. Accessed 13 May 2014.
22. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control 1992; 41(RR-17):1-19.
23. Ho-Pham LT, Nguyen UDT, Nguyen TV. Association between lean mass, fat mass, and bone mineral density: a meta-analysis. J Clin Endo-crinol Metab 2014; 99:30-8.
24. Erlandson KM, Kitch D, Tierney C, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS Lond Engl 2013; 27:2069-79.
25. Cotter A, Sabin CA, Simelane S, Macken A, Kavanagh E, Mallon PWG. Lean mass has a greater effect on bone mineral density than fat mass: data from a cohort of HIV-positive and HIV-negative subjects. 14th European AIDS Conference, Brussels, Belgium, October 16-19, 2013. (abstract PE11/29). http://www.abstractserver.com/eacsabstractarchive/. Accessed 13 April 2014.
26. Yin MT, Modarresi R, Shane E, et al. Effects of HIV infection and an-tiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporos Int 2011; 22:1459-68.
27. Hernandez-Vallejo SJ, Beaupere C, Larghero J, Capeau J, Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell 2013; 12:955-65.
28. Zuccotti G, Viganò A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone 2010; 46:1633-8.
29. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746-54.
30. Anastos K, Lu D, Shi O, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther 2007; 12:1049-58.
31. Kinai E, Nishijima T, Mizushima D, et al. Long-term use of protease inhibitors is associated with bone mineral density loss. AIDS Res Hum Retroviruses 2014; 30:553-9.
32. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS Lond Engl 2012; 26:825-31.
33. Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS Lond Engl 2010; 24:2827-33.
34. Pinto Neto LFS, Ragi-Eis S, Vieira NFR, et al. Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. J Clin Densitom 2011; 14:434-9.
35. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PloS One 2011; 6: e23688.
36. Mulligan K, Glidden D, Gonzales P, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study. Conference on Retroviruses and Opportunistic Infections 2011: Program and Abstracts. Boston, MA; February 27-March 2, 2011. (abstract 94LB).
37. Grijsen ML, Vrouenraets SME, Wit FWNM, et al. Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis 2013; 207:386-91.
38. Mulligan K, Harris DR, Emmanuel P, et al. Low bone mass in behavior-ally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis 2012; 55:461-8.
39. Brown TT, Chen Y, Currier JS, et al. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 1999 2013; 63:323-30.
40. Overton ET, Chan ES, Brown TT, et al. High-dose vitamin D and calcium attenuates bone loss with ART initiation: results from ACTG A5280. Conference on Retroviruses and Opportunistic Infections 2014: Program and Abstracts. Boston, MA; 2014. http://croi2014.org/sites/default/files/uploads/CROI2014-Final-Abstracts.pdf. Accessed 17 July 2014.